HRI Activator Compounds Modulating eIF2α Phosphorylation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for diseases related to eIF2α kinases, such as β-thalassemia and cancer, lack effective small molecule activators that specifically target HRI, leading to inadequate modulation of eIF2α phosphorylation and downstream effects.

Innovation Solution

Development of novel compounds, including those of Formula I and Formula II, which are specific HRI activators, designed to modulate eIF2α phosphorylation and inhibit cancer cell proliferation by displacing inhibitors and promoting auto-phosphorylation events, thereby activating the kinase domain to bind eIF2α.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current treatments for eIF2α kinase-related diseases are used, then disease management is maintained, but effective modulation of eIF2α phosphorylation and downstream effects is inadequate

Engineering Contradiction:

Improveeffectiveness of disease treatmentVSAvoidmodulation capability of eIF2α phosphorylation

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by modifying molecular structure parameters of small molecule compounds to create specific HRI activators. The compounds of Formula I and Formula II are designed with specific structural parameters (substituents R1-R6, ring structures) that enable them to bind to HRI and induce eIF2α phosphorylation, thereby changing the biochemical parameter of kinase activation to achieve effective disease treatment.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If specific HRI activators are developed, then eIF2α phosphorylation is effectively modulated, but the complexity of compound design and synthesis increases

Engineering Contradiction:

Improvespecificity for HRI activationVSAvoidcomplexity of compound structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies segmentation by dividing the HRI activator compound into distinct structural segments or domains. Formula I and Formula II compounds contain separable functional groups (aromatic rings, substituent positions R1-R6, linker regions) that can be independently optimized. This segmentation allows medicinal chemists to modify specific segments to enhance HRI specificity while managing overall molecular complexity.

Inventive Principle:

Principle #1Segmentation

3Reliability

If small molecule activators are designed to displace inhibitors and promote auto-phosphorylation, then kinase domain activation is achieved, but the precision of binding and activation mechanisms must be maintained

Engineering Contradiction:

Improveactivation of kinase domainVSAvoidprecision of eIF2α binding

Core Design Contradiction:

ReliabilityVSManufacturing precision

Solution Approach 1:

The patent applies the intermediary principle by designing small molecule compounds that act as mediators between the HRI kinase domain and eIF2α substrate. The compounds of Formula I and Formula II serve as intermediary agents that bind to HRI, induce conformational changes, and facilitate the phosphorylation transfer to eIF2α. This intermediary mechanism allows precise control of the activation process while maintaining binding specificity.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20240076272A1Activators of Heme Regulated Inhibitor Kinase (HRI)

Publication Date: 2024.03.07 THE BRIGHAM & WOMEN S HOSPITAL INC

AI summary

The present application provides compounds that modulate the activity of one or more eIF2α kinases. Pharmaceutical compositions and methods of treating diseases related to one or more eIF2α kinases are also provided.